Found: 12
Select item for more details and to access through your institution.
Elimination of tucatinib, a small molecule kinase inhibitor of HER2, is primarily governed by CYP2C8 enantioselective oxidation of gem-dimethyl.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2022, v. 89, n. 6, p. 737, doi. 10.1007/s00280-022-04429-z
- By:
- Publication type:
- Article
Feasibility of therapeutic drug monitoring of sunitinib and its implications on response and toxicity in patients with metastatic renal cell cancer.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2022, v. 89, n. 6, p. 751, doi. 10.1007/s00280-022-04432-4
- By:
- Publication type:
- Article
Effectiveness and safety of sorafenib for renal cell, hepatocellular and thyroid carcinoma: pooled analysis in patients with renal impairment.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2022, v. 89, n. 6, p. 761, doi. 10.1007/s00280-022-04428-0
- By:
- Publication type:
- Article
An evaluation of the interaction of pixantrone with formaldehyde-releasing drugs in cancer cells.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2022, v. 89, n. 6, p. 773, doi. 10.1007/s00280-022-04435-1
- By:
- Publication type:
- Article
Comparison of docetaxel pharmacokinetics between castration-resistant and hormone-sensitive metastatic prostate cancer patients.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2022, v. 89, n. 6, p. 785, doi. 10.1007/s00280-022-04433-3
- By:
- Publication type:
- Article
Dose-dependent bioavailability, absorption-rate limited elimination, and tissue distribution of the ATR inhibitor BAY-1895344 (elimusertib) in mice.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2022, v. 89, n. 6, p. 795, doi. 10.1007/s00280-022-04436-0
- By:
- Publication type:
- Article
The effects of two gold-N-heterocyclic carbene (NHC) complexes in ovarian cancer cells: a redox proteomic study.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2022, v. 89, n. 6, p. 809, doi. 10.1007/s00280-022-04438-y
- By:
- Publication type:
- Article
A phase I pharmacokinetic study of copanlisib in Chinese patients with relapsed indolent non-Hodgkin lymphoma.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2022, v. 89, n. 6, p. 825, doi. 10.1007/s00280-022-04417-3
- By:
- Publication type:
- Article
Risk factors of proteinuria and potentially protective effect of renin–angiotensin system inhibitors in patients with renal cell carcinoma receiving axitinib.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2022, v. 89, n. 6, p. 833, doi. 10.1007/s00280-022-04408-4
- By:
- Publication type:
- Article
Correction to: Evaluation of the absolute oral bioavailability of the anaplastic lymphoma kinase/c-ROS oncogene 1 kinase inhibitor lorlatinib in healthy participants.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
Editorial Expression of Concern for: Induction of apoptosis by [6]-gingerol associated with the modulation of p53 and involvement of mitochondrial signaling pathway in B[a]P-induced mouse skin tumorigenesis.
- Published in:
- 2022
- By:
- Publication type:
- Editorial
Retraction Note to: MicroRNA‑30c‑regulated HDAC9 mediates chemoresistance of breast cancer.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice